All News
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.
Read Article
The art of talking about risks with our patients
On the first day of EULAR 2024, I am debating Janet Pope.
Read Article
And were are on folks!! 🎙️
Delighted to join @RheumNow faculty again this year
I will be covering RA and PsA topics during #EULAR2024
Don’t miss our Daily recaps live 6pm
Oh and if you see me around, come and say Hi! https://t.co/TrQ9b3WeSy
Aurelie Najm AurelieRheumo ( View Tweet)
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Australian studyshows knee OA pts unconsciously believe that activity may be dangerous to their condition, despite medical advice telling them otherwise. 69% of people with knee pain had stronger implicit (unconscious) beliefs that exercise was dangerous https://t.co/iytfpcGvD8 https://t.co/N183ffYfPP
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 Opening Ceremony. @DanielAletaha highlighted values of @eular strategies that have been achieved:
Patient centredness ✔️
Innovation ✔️ - RheumaFacts, ENTRI, Exams
Inclusivity ✔️
To strive on 3 other values by next year under President-Elect @XBaraliakos @RheumNow https://t.co/wDR2vtv3I2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📄 #EULARAdvocacy Chair @carmona_loreto discusses the @eular_org manifesto at the #EULAR2024 opening ceremony
🔗You can read the full manifesto and find out more here: https://t.co/6CZuSYpiLl
@RheumNow https://t.co/DYcU9I6rmR
Mrinalini Dey DrMiniDey ( View Tweet)
« We must work together to achieve a future where RMDs are no longer an invisible problem »
Wise words from @carmona_loreto during Opening Plenary session #EULAR2024
@RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
#AB1039 Spanish study 76 LN patients postrenal transplant: 77% females, HTN (68%), LN class IV (42%), mean age 55. Graft loss in 35.5% b/c of acute rjx (22%), chronic rjx (22%), acute w/chronic rjx (22%), graft thrombosis 14.8%, recur LN (11%) #EULAR24 @rheumnow https://t.co/d82i0Z7LUB
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
Dr. John Cush RheumNow ( View Tweet)
Final countdown to #EULAR2024 and we'll be there. We'll be sharing recaps, videos, and more. Are you ready for it?! https://t.co/BSrRATfxwt
Dr. John Cush RheumNow ( View Tweet)
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
https://t.co/tmCra58mYf https://t.co/KbMIDipvpI
Dr. John Cush RheumNow ( View Tweet)
Danish Registry study of 1.9 million chronic pain pts, shows chronic use of medicinal cannabis (5391) is assoc w/ a significant risk of new-onset arrhythmia {180d RR 2.07; 1-year RR 1.36). No significant association for acute coronary syndrome https://t.co/VT3X8lVWaD https://t.co/BMqVapFkuU
Dr. John Cush RheumNow ( View Tweet)
CATCH cohort study of 547 Early RA pts shows higher Tender > Swollen joint differences is assoc. w/ worse n patient-reported outcomes (PROs) in all domains (phys function, social , pain, sleep problems, fatigue, anxiety, depression) -- Isnt this FM ? https://t.co/4Bk8VGQNB6 https://t.co/K7kO5q990v
Dr. John Cush RheumNow ( View Tweet)
Cohort study of 25 315 women followed 25 years shows adherence to the Mediterranean diet associated with a 23% reduced all-cause mortality - explained by lipids, inflammation markers and BMI; more than cholesterol or glycemic measures https://t.co/nprDKXMWKp https://t.co/ofoHd8xF8D
Dr. John Cush RheumNow ( View Tweet)
Prospect study 174 SLE HCQ-Rx pts w/ whole-blood HCQ levels during pregnancy. 30 w/ flares(17%; 2.3% severe) & 28(16%) adverse preg outcomes. HCQ levels didnt predict APOs. BUT low (≤500) or no (≤200 ) HCQ levels assoc w/ severe maternal flares (9-13%) https://t.co/CHdd9Tuamk https://t.co/fFTr5MpiCx
Dr. John Cush RheumNow ( View Tweet)
Medicare & Optum claims data study of 2851 #RA pts w/ breast cancer (BC). In 3 mos before BC 27028% received bDMARDs. W/in 1st 3 yrs post-BC Dx 24-26% were receiving bDMARDs. 70% of RA pts on steroids without change w/ time https://t.co/51NcXv0xyc https://t.co/461NZiFvDO
Dr. John Cush RheumNow ( View Tweet)
National Psoriasis Foundation’s 2019 Annual Survey of 1,570 #PSO pts found among 801 w/ PsA most (59.6%) report unacceptable levels of disease activity, which is associated with increased prevalence of depression and limitations in social participation. https://t.co/HtWcAhZ6Zu https://t.co/pdC4IjIxmj
Links:
Dr. John Cush RheumNow ( View Tweet)
Flavinoids (herbs, cherries, berries) have clinical efficacy in #Gout. Review of the mechanisms of flavonoids in gout includes:
- Cox-2 inhibition
- Lowers xanthine oxidase activity (mediated thru inflammasome, NOD/TLR4, NFKB, OAT1 & OAT3 transporters https://t.co/UC55GGZBCJ https://t.co/L6nE3BMIj1
Dr. John Cush RheumNow ( View Tweet)
Molecular Profile for Cardiovascular Risk in Rheumatoid Arthritis
A new study led has managed to establish, for the first time, the molecular profile of those patients with rheumatoid arthritis who have a higher risk of suffering cardiovascular events.
https://t.co/VVKR2G91VQ https://t.co/ZZNLJpoyNA
Dr. John Cush RheumNow ( View Tweet)